Q4 2019 Earnings Call
Ladies and gentlemen, today's conference scheduled to begin shortly please continue to standby and thank you for your patience.
For standing by welcome to the fourth quarter 2019 prisons Elmer.
Earnings Conference call at this time, all participants in listen only mode. After the speakers presentation. There will be a question and answer session to ask a question. During this session you need to press star one on your telephone.
Please be advised that today's conference maybe recorded if you will hear any further assistance. Please press star zero.
I'd now like turn the conference over to your Speaker Day, Mr., Bryan Kipp, Vice President Investor Relations. Please go ahead Sir.
Thanks, Catherine good afternoon, and welcome to the Perkinelmer fourth quarter and full year 2019 earnings conference call with me on the call our plot, saying, President and Chief Executive Officer, and Jamie Mock Senior Vice President and Chief Financial Officer, If you've not received a copy of our earnings press release, you may get one from the Investor section about.
Website at Www Dot Perkinelmer dot com.
Please note this call is being webcast live and will be archived on our website until February 10 2020.
Before we begin we need to remind everyone of the safe Harbor statements that we have outlined in our earnings press release issued earlier. This afternoon and also those interest SEC filings.
Statements or comments made on this call maybe forward looking statements, which may include but are not necessarily limited to financial projections or other statements of the company's plans objectives expectations or intentions.
These matters involve certain risks or uncertainties.
The company's actual results may differ significantly from those projected where suggested by any forward looking statements due to a variety of factors, which are discussed in detail in RCC filings.
Any forward looking statements made today represent our views only as of today, we disclaim any obligation to update forward looking statements in the future even if our estimates change. So you should not rely on any of the days forward looking statements as representing our views as of any date after today.
During this call we will be free to certain non-GAAP financial measures a reconciliation of the non-GAAP financial measures. We plan to use during this call to the most directly comparable GAAP measures is available as an attachment to our earnings press release.
To the extent, we use non-GAAP financial measures. During this call that are not reconciled to GAAP in that attachment we will provide reconciliations promptly.
Now pleased to introduce the president and Chief Executive Officer, a perkinelmer a lot, saying a lot.
Thank you Brian I'm good evening everyone.
I'm pleased to report that book in other countries strong furnished to 29 pm.
Reported revenue in the fourth quarter, increasing 6% Yodle, where you're an adjusted earnings per share growing 14%.
Beating both the top and bottom line Oh from previous guidance.
Revenue in the fourth quarter was 806 million.
Representing organic growth of 5%.
No not adjusted earnings per share was done a pretty fights.
I'm sorry to reflect on 29 team.
Robert transformation, we made as an organization that's what does an excellent position to accelerate profitable growth and advanced outcomes around the world and 2020 and beyond.
I have no doubt that these positive changes will become increasingly about and external stakeholders over the coming quarters in years.
From a financial perspective, we delivered strong performance in 29 team across our businesses.
Despite evolving macro headwinds.
We delivered organic growth of 5%.
170 basis points of margin expansion.
And 14% adjusted earnings per share growth.
Jamie will discuss our financial results in greater detail.
As you are familiar.
Last summer, we aligned our go to market approach and combined our R&D teams.
And Bob <unk>, our regional commercial leaders to make decisions there was a two customers.
An encouraging our R&D team to trim differently and leverage the but so far capabilities across the end markets we serve.
To double up one book flow solutions that address evolving customer needs.
We entered 2020 as a new highly collaborative organization that has significant opportunity to leverage our differentiated capabilities to accelerate positive outcomes for the betterment of people and the out environment.
All in all I'm extremely proud of all or part, though 2000 employees, who come to work every day, but then posey ASM around our mission innovating for how did the award.
Oh relentless focus on drugs for me to innovation and operational excellence.
Really strong commitment to meet him be ever changing needs of our customers.
Oh just share a few examples from the fourth quarter, that's we've seen our transformation efforts paid off.
Our targeted focus on southern critical issues impacting the future of signs and healthcare enabled us to achieve new milestones by working with our customers and partners.
But then the diagnostics business be it'd be a pretty will afford us be neil need to create and gummies m. Good hesitant sounds good enforced commercially available I see.
Screening newborns affected by Duchenne muscular dystrophy.
Booking almost good is specifically designed for screening newborns and there's a cost effective they.
The screen for DMD. They do do your dusting approach using the secret M. A C and then B M D gene analysis.
Screaming newborns not only prevents b M b patients and their families from an unnecessary diagnostic Odyssey.
But it also ensures timely treatment for disease that could otherwise go undetected for years.
Wow Opera Brightree DMD, good booking is participating embedded project muscular dystrophies consented pilot program.
The screen newborns in New York State fiduciary.
The program aims to screen hundred thousand babies about how all those born each year in New York, well, what a two year period.
Taking a step back for a moment.
Then we think about positive an accelerated outcomes, you're looking at the whole human cash cycle, not just silo points, along the diagnostics and therapeutics spectrum.
Oh advancements in newborn screening so just the DMD. Good for example, late into a largest strategy focused on the full continuum from family running two maternal fetal newborn how childhood and family health.
To this and you got excited about some of the truly novel solutions that we have enough pipeline today.
And hopefully we'll be discussing more in the month and years ahead.
Turning to dive on new go to market strategy is fundamentally shifting how we are approaching new analytical market opportunities.
As I mentioned at the recent conference cannabis is Oh leave an example of this new go to market. The approach that we hope to replicate going forward.
We have progressed from even relatively nascent business in only 2018 to 26 million Infiniband revenue from kind of just testing in 29 pm.
Thanks to our airports to really understand the voice of the customer and provide an end to invoke flow solution.
Including some food.
Quality and safety testing and analytics capabilities.
The continued to show a strong commitment to this rapidly expanding market and to broaden our distribution reach.
This past December I am Jay Bis gone, we announced that amateurs scientific all leading kinda beside attempt lapped technology player and testing standards leader Who's now for our cannabis and hem testing portfolio to their north American customers.
Our success in developing complete Voeckler solutions is also serving as a key differentiator across our life Sciences portfolio.
The acquisition of this bio for example.
Just tracking ahead of our deal model.
We now can provide end to end solutions in the discovery stage on target identification lead generation and optimization in preclinical for both pharma and biotech research.
During the fourth quarter alone.
Introduced several new CES bio kits for phosphorylated and total protein and biomarker detection.
And with our reagent R&D for all book in a month technologies now consolidated at that site and God only fronts.
Expect an uptick in drug discovery screening reagent innovation in the future.
A final example off on new strategy coming to life is within the fast growing food market.
Did we are already the divorce integrating some focusing on more food assets into the means I'm, saying sales channel.
To take advantage of its commercial Brett customer intimacy and local domain expertise.
One example of this in action is without recently introduced I'd Checker BC 6800 technology from Portland.
Automates analysis, and increasing testing I could you see a friday, the ice hockey quality markers.
The new solution also eliminates the need for traditional labor intensive steps and deliver most accurate results with five to 10 minutes.
Right, so being as it keeps people in People's diet.
Helping to ensure the quality of this might go green is important for the increasing research and planting demands of the ever growing global food chain.
Why is amazing was only consolidated for part of the fourth quarter Veeva leased with its double digit growth and only synergies.
I'd be looking ahead.
Good to go do a success will be our ability to execute across the company on three key priorities, we have laid out for <unk> organization. This year.
And shooting a customer first mindset.
In a waiting to address critical held and scientific challenges.
And evolving our employee expedience.
From the customer standpoint.
Providing exceptional experiences with Buck in Oman.
Means that we are improving our tools processes and responsiveness to deliver solutions, Ben there and how our customers need them.
On the innovation fund.
This year, you will see us for the partnerships with customers an industry organizations to accelerate the visibility and development of new offerings across our end markets.
And internally.
We'll continue to work on creating a culture that drives greater cross company collaboration than ever before.
Before I hand, it over to Jamie I want to briefly provide an update on validus.
Earlier this month deem hosted people from the investment community at our lab in Pittsburgh, Pennsylvania.
That'd be discussed Validus, and a broader booking more genomics strategy.
Specific to Validus the key messages that we tried to drive home Berger.
Validus and I P. P is they test for every woman.
To its high precision and low no called right.
The system has been your vote flow advantages over ngs.
Customer feedback continues to remain positive.
And I'd be market is sizable and growing rapidly.
We truly believe that Validus and IBP will play a pivotal role in helping to democratized noninvasive prenatal testing.
Across the build over the next few decades.
In terms of placements in 2019, we achieved 28 systems and we continue to have a whole different huh.
For 2020, our plan is to end the year between 50 to 55 installations dauteuil.
Which would imply another 20 to 27 systems this year.
Up from 10 placements in 28 Dean.
And 18 placements in 29 Pete.
All told I'm confident that via on that I bought as an organization.
Why is devoted a lot of internal changes in 29 pm.
No well positioned as we turned the page to the next chapter of the booking and most Jody.
I look forward to shedding I've continued progress throughout the year.
I'll now hand, it over to Jamie to discuss our Q4 and 2019 financial results in more detail as well as our 2020 guidance.
Thanks, a lot and good evening, everyone before I start I want to points everyone's attention to our fourth quarter earnings call presentation, which has been posted on the investor section of our web site under financial information.
The goal. This document is to drive additional transparency and simplicity around the company in our quarterly performance.
Today I plan to begin by highlighting the fourth quarter, then I'll provide some additional color on our served end markets in financial metrics.
Lastly, I'll finish by providing a look back on our 2019 performance and our financial outlook for 2020.
[noise] jumping in we're pleased with our fourth quarter results in full year 2019 performance.
Market conditions were in line with our expectations entering the fourth quarter.
As they have all year, our growth accelerators continued to perform well led by your opinion, which grew at a double digit clip on broad based global demand.
And cannabis, which more than doubled year over year.
Our genomics testing business remains on track to complete the Branford to Pittsburgh consolidation by the end of the first quarter.
And then it just no minimum continues to build.
As Phil I'd mention the recent granting of the advantages and I P. T. P really code by the American Medical Association was an important development in December that favorably positions. We entered this diagnostics for 2020.
Our 2019 acquisitions of spiral Mary Jane and Solace, all performed well during the quarter <unk>.
And concluded the you're well positioned to be strong incremental contributors in the years ahead.
<unk>.
From an operational standpoint prior actions to reduce organizational complexity of and undoubtedly made us a nimbler organization.
Our 50% organic incremental margin in 2019 is a direct product of the increase transparency and accountability across the organization.
Turning to the fourth quarter results.
We achieved 5% organic revenue growth with broad based momentum across our portfolio.
Adjusted reported revenue grew 6% to eat hundred 6 million.
And included a 1% foreign exchange headwind in a 2% net acquisition tailwind.
By business diagnostics, representing 38% of total sales grew 5% organically driven by our immuno diagnostics and reproduction reproductive health business lines.
Discovery and analytical solutions, representing 62% of total sales also grew 5% organically due to continued strength in life Sciences, and a rebound in our core food business.
I will provide some additional color on both businesses in a moment.
On a geographic basis organic growth trends largely paralleled what we experienced during the third quarter.
Asia Pacific in Europe , both grew mid single digits, while the Americas grew low single digits.
Operationally, we are extremely pleased with our performance in the fourth quarter and we continue to see significant potential to improve our profitability moving forward.
Adjusted operating margins expanded 210 basis points in the fourth quarter to 23.9%.
Driven by productivity mix cost out actions and some timing.
As Todd mentioned adjusted earnings per share of $1.35 was an increase of 14% versus the fourth quarter of 2018 and three cents ahead of our guidance.
Looking further into the key drivers within our segments, let's start with our diagnostics business.
As mentioned in my earlier remarks organic revenue grew 5%, which was off a strong 14% organic growth comparison in Fourq you 18.
Immunodiagnostics grew low double digits.
I mean led the way with the mid teens growth rate, which was broad based on both a geographic and product basis.
Geographically the U.S. in Western Europe , both grew over 20% in China grew at a healthy mid teens clip.
Reproductive health grew low single digits organically driven by expanded coverage in Asia Pacific.
We highlighted expanded newborn screening in the Philippines on our last earnings call.
Additionally, we also benefited from expanded screening programs in Japan, and Vietnam in 2019.
Paralleling the third quarter are applied genomics business remained soft declining high single digits in the fourth quarter.
Momentum in our Ngs and nucleic acid extraction reagents was more than offset by softness in automated workstation and robotics product segments.
Turning to discovery and analytical solutions organic growth of 5% in the fourth quarter was driven by our life Sciences and food franchises.
By end market, we experienced high single digit organic revenue growth in pharma biotech.
Propelled by our discovery and informatics product lines.
Our informatics business continues to perform well growing double digits in the fourth quarter.
Perkinelmer signals solutions are increasingly gaining traction amongst the top pharma biotech and contract research organizations at signals helps drive increased collaboration improve efficiencies and accelerate time to discovery for R&D scientist.
The applied markets were up mid single digits in the quarter driven by an improvement in our core food business continued strengthen our Canada solutions and a modest sequential improvement in Asia Pacific Industrial environmental safety demand.
Overall industrial environmental grew approximately 1%.
Food was up mid teens with core food up mid single digits in Kansas up over 150% year over year.
Shifting to below the line items adjusted net interest and other expense for the fourth quarter was approximately $13 million.
Our adjusted tax rate was approximately 16%.
Turning to the balance sheet, we finished the year with approximately $2.1 billion of debt and $192 million of cash.
Free cash flow in the quarter was 192 million an adjusted free cash flow in the quarter was 193 million.
As a reminder, the difference between reported and adjusted number is due to cash payments associated with prior acquisitions.
For the year, we achieved an adjusted free cash flow conversion of 70%, which was an improvement versus 2018.
While this was short of our 80% estimate we understand the fundamental levers of the shortfall and we feel confident that we have the right action plans in place to improve the conversion rate over the coming years.
Finally, we exited the quarter with a net debt to adjusted EBITDA ratio of approximately 2.8 times.
Turning to the full year results.
We're very pleased by our performance the progress we made a lining or our organization and the relentless focus of our entire organization displayed during times of internal change and external macro uncertainty.
For 2019, we posted 5% organic revenue growth and 14% adjusted earnings per share growth.
Except for core food end markets performance played out as we expected entering the year and conditions were consistent throughout the year.
From an adjusted EPS standpoint, we beat the midpoint of our initial guide by seven cents due to our strong margin performance and improve tax benefit which more than offset a slight organic shortfall.
As we transition to 2020, we remain excited by this prospects for growth given the portfolio transformation over the past few years, including our recent acquisitions the momentum of our growth accelerators, and our new organizational structure.
Consequently for 2020, we expect 5% to 6% organic growth and reported revenue to be between $3.25 billion and $3.09 billion, including 12 million from foreign exchange headwinds and approximately 35 million of contributions from acquisitions.
We are forecasting full year adjusted EPS guidance of $4 in 50 cents to $4 in 60 cents up 10% to 12% and including a two cents headwind from foreign exchange.
We expect to expand our operating margin adjusted operating margin by 80 basis points.
Finally, we anticipate 54 million in adjusted interest and other expenses, a 16% tax rate and our share count to average 112 million for the year.
Embedded in this full year guidance the impact from a 53rd fiscal week in 2020.
As most of you know Perkinelmer operates on a 364 days fiscal calendar.
Therefore, similar to the year 2015 every fifth year includes the 50 Threerd week.
For 2020, we anticipate the impact of the 50, Threerd week will be approximately $10 million to $15 million of revenue.
However, given the extra week of expenses the extra week will dilute our adjusted operating margin by 25 to 30 basis points and adjusted EPS by negative three to five cents.
For modeling purposes, the extra week falls into the first quarter.
We anticipate adjusted free cash flow conversion of 75% to 80% during the 2020 fiscal year, which would represent a 5% to 10% improvement year over year.
We are acutely focused on improving our free cash flow conversion in a prudent way, while balancing growth and profitability.
There's going to be a two to three year process to get back to the 85% to 90% range.
Turning to the first quarter 2020, we are forecasting reported revenue of 700 million, representing 6% organic revenue growth, including a foreign exchange headwind of approximately 8 million versus the comparable prior period.
In terms of adjusted earnings per share gains for the first quarter, we are forecasting 70 cents.
We expect the impact from the extra week to dilute our first quarter operating margin rate by 90 to 110 basis points.
Excluding the extra week foreign exchange headwind and higher tax rate earnings in the first quarter would be up 9% to 12%.
Again, all just as noted in the last page of our fourth quarter earnings presentation, which I mentioned earlier.
Before I hand, it back to the operator, the growing Corona virus outbreak is a concern on multiple fronts.
First our thoughts and prayers go out to those impacted.
Teams across Perkinelmer actively working to develop solutions to control and hopefully help stop the spread of this infection.
That said, we have not embedded any financial impact in our first quarter or full year guidance.
If the epidemic continues to grow it could negatively impact our euro immune and symbio franchises given patients in China may avoid going to the hospital for immunology and infectious disease testing.
There are currently a lot of unknowns. Therefore, we think it is prudent to highlight this risk going into the year.
This concludes my prepared remarks, operator at this time, we would like to open the call to questions.
Thank you as a reminder to ask a question you know press star one on your telephone should draw your question press the pound.
Please limit yourself to one question and one follow up.
And our first question comes from Catherine Sheltie with Baird. Your line is open.
Hey, guys. Thanks for that question I, just wanted to go back to that first quarter guide.
You know if we back out the extra week I think the first quarter come closer to 3.5% to 4%, despite having a fairly easy comp with the government shutdown. We saw last year. So can you just walk us through the the pluses and minuses off of what you think and normalized growth rate should look like in that first quarter.
Yes, Thanks Catherine.
I'll take this one.
So I think you know if you back out the extra week, it's more like 4% to 4.5% in the first quarter, which is down versus everything every quarter in the year 2019, we reported 5% organic growth. So it's a similar comps throughout the year I think there's two things largely that are affecting us in the first quarter first it genomics testing if you remember 2019.
I mean, we started off very high, particularly in the sequencing part of that business and.
And so that had a great first half in a little bit softer second half due to the consolidation we expect that to continue into the first quarters that probably half a point of organic growth by itself. What we're planning on in the first quarter here.
And the second area is applied genomics. Similarly, what I mentioned on robotics and automated workstations that had a stronger first half weaker second half were expecting that to continue into the first half year.
And so those two things really are the only difference between our 5% organic run rate that we saw throughout the year, including the fourth quarter and walking into the first quarter here.
Okay and on that applied genomics business, we've seen a number of data point, suggesting that DTC microarray industry will continue to have some meaningful headwinds. This year now you have some exposure there. So how do you think about that business returning to better gross.
Yeah cuts and this is for a lot. So I think in or they are our exposure to the Beast DTC market is not a much more still far relationships. There are pharma and on the newborn screening side you know the the the thing that we're just going through his deconsolidation piece that we as weve.
Pointed out on the Oh by the end of Q1 that should be resolved. So we don't be at this point don't see that's not exposure to DPC is not.
Too much.
Hi, good thank you.
Thanks, Kevin.
Thank you. Our next question comes from Dan areas with Stifel. Your line is open.
Afternoon, guys. Thanks.
Hi, Dan maybe just on Hey, Jamie maybe just on vantages since plod touched on it and we were just out there what kind of revenues are you thinking that the placements and utilization will yield for 2020, and then along those lines can you just talked about sort of talking the visibility that you have when you think about the labs that will get you. There is there is.
Sure a volume trajectory that you feel confident about at this point everything still kind of fluid in terms of what their ramp it looked like.
Yeah, Dan you know in fact as a matter of fact do you have a very healthy funnel and we are actually in the currently in the process of shipping and installing several systems.
As I've said earlier and I have a you know our focus right now continues to be that the earlier adopters I'd be flawless experience. If you just look at what I pointed out earlier 50 to 55 installations. Dan you know, we've placed and systems in 2018, 18 systems and 29 PM and the implied.
Range between 20 to 27 in 2020.
So from my perspective, we think installations are an important metric to track only on and the products lifecycle.
But in the end you never actually as I've said, our goal is to democratize advantages I might be.
So are there does appear to be are focusing and also bid the a and IP P. P. OLED code that gives us several advantages in the U.S. once that is issued.
So from a priority perspective, you're looking at the number of installations, Glenn getting the clinical data out and working on the P. OLED code.
Okay. So it sounds like that's TBD on a forecast preventative.
Yeah, I think all from a revenue perspective, our guidance will be to continue to monitor the number up installations.
Okay.
Okay, and then just secondly, Jamie if I just think about the topline guide and I take out the half one or so that you're getting from the extra week, that's 5% organic at the midpoint, which is in line with 2019, which was a year, where you had some organizational issues and then either one off or maybe somewhat unlikely to repeat elements.
And I think at the end of this year you should also be getting a little bit of juice from amazing. So I guess, how much of the outlook for 2020 on the organic side is conservatism to start the year versus maybe something that's under appreciated about either the Dx ramp where the factors that are at play India, Yes.
Yes. Good question. So I mean, we just kinda talk through the end markets here, Dan. So I would say, where we have a little bit of incremental caution is around a life sciences and immunodiagnostics, let's start with Immunodiagnostics, obviously, you're all immune leads the way there they have been mid teens for quite some time, but I think we're pretty consistent.
In saying that we're going to model them at 12% organic growth. So I think we expect a little bit down downtick there.
Hi Sciences, I don't think we've seen anything but a funding levels have remained very strong and so we're hopeful that it continues but I'd say, there's probably more downside and there is the upside so I'd say, that's where we're cautionary.
Conversely, you know if you look at a food and applied genomics food if it what we've talked about in terms of some kind of rebound in the core and we had at least one data point here in the fourth quarter should should provide some upside offsetting that I don't anticipate cannabis being as large an incremental contributor this year, so that those kinda offset.
At a little bit there and then applied genomics once we get through the first half or we'll see how its going but hopefully that has a little bit of easier comp issue feminists comp or as well in the second half era.
So overall I you know to answer your question, probably a little bit cautious in life Sciences, immuno diagnostics, maybe a little bit upside and food and applied genomics, yeah, Theres pretty study.
Okay. Thanks, a bunch.
Yep.
Thank you My next question comes from Derrick.
Bank of America Your line open.
Hey, Thanks, So couple of questions.
I think the first one.
Did I think some companies, but we don't have as much exposure here biting some companies where.
Flagging that.
They didnt expect a significant budget flush during the fourth quarter from from their customers as in prior years I'm. Just wondering what you saw in terms of.
Incremental spending and just sort of what was sort of like the year end budget activity.
Yeah, it's always difficult to tell Derek but I don't think we saw much you know in terms of life Sciences, I actually was little soft in the Americas in the fourth quarter applied markets hung in there in the fourth quarter. So maybe there's a little bit off there, but I'd say, it's difficult to tell and overall nothing out of the ordinary here.
Okay and just on the China appreciate the comments on the credit virus Benny I, we've been getting some questions. Today, just given that you do have an infectious disease testing business.
That the that you've got I'm, just sort of getting people wondering would you are you testing for it are you going to see potentially any incremental headwind sales into your diagnostics products to potentially offset some of the headwinds you're referring to.
And maybe I'll take that so we are in the process of developing a PCR and an antibody I see a PCR there's generally a frontline assay during an outbreak and we are making strides, but we do have predicted through the Oh cfd of its is not the M.P.A. a approval process and they are working.
With us and Bill Sutherland to other entities to get to frontline testing I say out you know again most of the focus right now is doing its more from a CSR perspective, just to make sure that we have an assay that we can use for testing.
What's the commercial impact of that I would say at this point is unknown.
Thanks, Jamie if I can squeeze one more in so if you.
If you adjust for the extra week about 100 and.
Hundred 510 basis points of implied op margin expansion in 2020, I guess is that a.
I mean, how sustainable is that sort of like 100 basis points number.
On a go forward basis means they're incremental you're you're sort of at your 22 ish percent operating margin target you put out there for years ago is there upside to that number.
Yeah, I mean, I like we've been saying that we see a lot of room for continued expansion in profitability here and I don't think 22% was ever a stopping point.
We see that ultimately overtime getting up into the mid twentys or how much can be done in the year 2020. We think you know 100 basis points ex the extra week is a pretty healthy clip coming off 170 in 2019.
To your point I mean, we guided in 2000, 1900, 20, 250 and ended up beating that at 170, So you know or could there be upside to the 80 basis points there were guiding sure.
But I think we're more focused on long term and putting programs in place to get this to the mid twentys.
Thank you and our next question comes from Vijay Kumar with Evercore ISI. Your line is open.
Hey, guys. Thanks for taking my question, Jamie if I could I just touch on the margin question extra week incremental revenues can you walk us up like why margins would be down I would've thought the extra revenues benefited margins.
Yes, and you're talking for the quarter BJ or for the year a quarter and now for the year I'm just curious why incremental revenues have lower margins.
Yes. So if you look at it BJ the and then we tried to lay this out or in our earnings presentation. The exact numbers. So we feel like the extra week will provide 10 to 15 million of additional revenue, which is not what we experience. If you just take our total year and divide by 52 weeks, but.
We you know we think that that's the right amount of extra revenue coming into year. However, if you look at the expenses for an extra week that more than offsets that amount of gross margin.
So if you take the 10 to 15 million you get a 50% roughly there about gross margin then you add an extra week of operating expenses and an extra week of interest expense, it's actually dilutive to the year.
And I do like I said, we tried to lay that out both for the quarter and for the year on that last page in the earnings presentation.
Gotcha, and then not maybe just a follow up on the on that theme the extra week Matt.
One on Atlanta. This is there a are you guys know positioned to compete for tenders in Europe and relate to the extra week that 10 to 15 million us a sub 50 basis points on the topline.
Shouldn't it be just stepping in a few did the one week or 50 see something higher than what the implied on on the extra week us.
Let me start was actually week, then well that's going to jump in on minutes here. So.
You know, we think most of our customers and we actually saw this back in 2015 operate on a calendar year. So January onest of December 31st and if you look at where the extra days in on this year fall. They fall in the fringes. So take this quarter. For example December 30, Onest in 30 Onest for 2019 actually.
The fall in this fiscal year 2020, but we think that the revenue from that is mostly going to be spent in the 2019 and therefore it was recorded in our 2019 rep.
So once you back out a couple of those days you get down to let's say three more days.
And a lot of that is capex. Some of that is scheduled professional services. So not just a daily run rate and so therefore, you get down to some recurring revenues that are we believe in the 10% to 15% range, which ends up being appointed a half to 2%, which was very well I'm in sort of the third quarter 2015, we actually.
He said that it was 2% impact to our organic growth. So it's kind of similar operating assumption here.
In regard to your for the first part of your question. Yeah. We are began and are starting to participate in 10 does in Europe .
That's helpful problem and just to be carried the guidance has no assumptions around any potential linson, you're up on lantus.
Well I think what we are assuming basically is or what 20 to 27 installation. So some of it doesn't youre up some as a nation. Some as it into you some in the U.S., you're not sort of focusing on which put to collect and of which I'd be could Ben arbitrary wouldn't run.
But there will be some capex revenue that come from in our your guidance as well as some sample ramp as well.
Got it thank you guys.
Yep.
Thank you My next question comes from Steve <unk> Charles.
Wolfe Research your line is open.
Hi, good afternoon. Thanks for the time here I was hoping first if you could help unpack.
Oh, your thought process around reproductive and the 2020 guidance.
Birthrates, particularly in China were a headwind there in 2019, what do you expect for broader growth in that category and how you're thinking about the birth rate dynamic prospectively.
Yes, I think hey, Steve overall, we think reproductive health ticks up a little bit. So we've got vantages that should kick in some genomics testing that gets reported in there that should kick in some I don't anticipate we're not anticipating Annie good news on Birthrates, We think we've continued to see significant issues.
Particularly in China, we expect that to continue.
We had a lot of good APAC expansion that I mentioned.
Earlier in my prepared remarks around the Philippines in Japan, and Vietnam. So that has a little pressure. So net net there's probably a little bit of upside to reprice reproductive health year over year, but there were definitely planning on birthrates impacting us and well see where geographic expansion gets us.
Okay, and then not just for 2020, but maybe even front with the medium term bend wonder if he can speak for a minute about cannabis you mentioned that the growth in fact for Canada is in 2020, you expect to be somewhat smaller than it was in 2019 can you put any numbers around that and is that you know markets. It's just you know somewhat mature.
Word or is there a competitive dynamic you know why would that be slower growth after a big twin 19. Thanks.
Yeah, I mean, you know in cannabis this year performed extremely well, we're thrilled with the team the solution that we bring a prolonged mentioned that it was 26 million and revenue, which was up 10 million base that kind of incremental contributor is difficult to predict and we're not banking on that in this guidance.
We expect it to go up still at a double digit rate, but to go up another 16 million just feels like a or a significant planning assumption that we're not we're not it could happen, but that's not what we're banking on right now so the market still seems great. We'll see how states rollout I think theres a couple more that'll come online in 2020.
But I don't think we're gonna bank on that kind of incremental contributor this year.
Okay. Thank you for all the color here.
Thanks, Steve.
Thank you. Our next question comes from Tyco.
JP Morgan your line is open.
Hey, Thanks, sorry to go back to the one keys guide, but you know you mentioned a backing out the extra week TPS would have grown 9% to 12% 75 to 77 cents. That's still below consensus I would've thought with the recent reorganization efforts you would have a at least been able to guide to consensus. So can you talk about if there are other offset other than the extra week that are kind of weighing on EIP, yes.
First quarter.
Yeah, I mean hits that goes so in general a there's probably a little bit a mix difference or in the gross margin line versus what we kind of exited the last ended the year on.
As well as on the operating margin line, there's a little bit a comp timing year over year as well as some investments we're making in our growth accelerators in terms of bandages and cannabis et cetera that kind of set up a year. So overall, we think we'd be up about 40 basis points in the quarter, excluding the extra week.
And that continues to uptick throughout the year here.
Okay, and then a couple of quick cleanup that sounds like the Validus installed base went down it was 19 last quarter now you're saying 18 did is there something is a customer returns.
Why did it go down.
Mhm Tyco its 28, so buttons.
To be end of the TARP quarter will be one nine PM and that went to 28.
Maybe take a while we were saying was in 2018, we delivered 10 systems. In 2019, we added 18 systems to get to 28 next year, we're guiding somewhere in the 22 to 27. So we're we're make taking a methodical approach to increase our placements every year and be prudent on how we rolled.
These systems.
Alright, and then on your own immune mid teens into fourth quarter. You made a comment that you know that's maybe not sustainable we should be back to thinking 12, maybe 13% what what was there something in the fourth quarter that a lot of silver shoot to the upside.
No I mean look we hope that it's a mid teens I think we've been consistent in saying that we're gonna budget a year at 12% going forward you know that's what we planned and initial deal model throughout the first two years of Ah having your immune in the Perkinelmer family. It's grown mid teens both years, maybe it does again.
But we've always been consistent in saying, we'd like to plan. This at about 12% based upon terrific product introductions geographic expansion, including the U.S. and we just think 12% as it is a good operating assumption.
Okay, and then just one last quick one on the genomics the automation sounds like you're going to recapture half of it in the first quarter was that in line with your original expectation are we expecting to recapture most of that in the fourth quarter.
No not as much actually take a we're expecting that to persist into the first quarter. So some of the pressure we saw in the second half of 2019 were expecting to persist we keep Steve keep seeing things pushed to the right here from a demand perspective, and we're not banking on that that will change in the in the first half year naturally when you get to the.
Second half you get a a different comp.
If it's better than that we're happy but right now our operating assumption is that we're going to continue on with the growth rates. We saw in the second half of 2019 into the first half of 2020.
Got it okay. Thanks.
Thanks.
Thank you and our next question comes from Patrick Donnelly with Citi. Your line is open.
Great. Thanks, maybe just building on Tyco's question on Euro immune.
Can you just talk through how sensitive that businesses to the China Hospital volumes, maybe just give us color on call.
The volume per day looks like.
Broker.
Yeah, Patrick I think it'd be difficult to give a one bedroom par day I think you know as Jamie pointed out in his remarks, you know given the evolving situation right. Now you know all we are doing is highlighting the corona wider as thing you know you don't know what the impact of that will be you know.
Ends on how it plays out over the next few days or a or b.
I think the point that Jimmy made to Tyco's earlier question is that you're doing immune has done better than what you have forecasted in the deal model, which has been 12% over the past couple of yours, and we hope that it continues to do that right from our forecasting perspective, you have modeled at 12%.
Okay, and then maybe Jamie just want to cash flow appreciate the to 75% to 80% conversion guidance can you just talk about some internal initiatives you guys are folks on there I know you had some headwinds around receivables and inventory kind of extended out. Some some agreement terms can you just talk about the trends you're expecting in 2020, there the focus points.
Yes sure.
Thanks, Patrick So I mean, we've learned a lot about cash flow over the last a year here and we've made some progress not not where we wanted it to go too but definitely some uptick.
So the 2020 operating assumption is that working capital turns are basically static.
Unlike the last couple of years, where we've actually been reducing our working capital turns and it's been a headwind. So you know there's internal processes around things like filling in X., English accuracy, and timeliness and collection efforts et cetera, but really when you look at a receivables it's in three or four different business models.
And we expect some of that there is somewhat plateau in 2020.
We've seen terms changing particularly in China and some of the emerging markets that are much more developed now.
Informatics, we've started to sell a subscriptions on three year basis, a couple of years ago. So should we should expect some more cash from that cannabis we've been leaning into a little bit here. So the fundamentally no embedded in a 70, 580% is basically you know static from an efficiency standpoint, which will be great. Hopefully there is upside.
Certainly over the next couple of years will will drive that the second thing I'd say is around capital expenditures. So capital expenditures downtick I think about 20% this year.
We didn't repeat some of the investments in genomics ER and we've been kind of monitoring your immune I would say over the next couple of years. There are two remaining areas that require capital expansion.
That's.
A euro immune in China, we're building out a facility there and then our tools business in India is growing extremely well.
And we got to increase some of the facilities space there, but after that I don't think we see a lot of capital expansion. So we've kinda reduce it a little bit here it will be static for little while and then hopefully that downticks overtime.
Appreciate it.
Thank you and our next question comes from Doug Schenkel with Cowen Your line is open.
Hey, good afternoon, guys Im just going to ask three quick ones and then get back into the Q.
No I don't want to add some its background noise. So first.
Following up on past. That's question has that then or is there any formal change plan for incentive comp as it relates to free cash flow conversion on second one cents cents for growth side you had.
Mentioned revenue growth guidance for the year and three what are your capital deployment priorities for the year EPS target in terms of capital you intend to deploy and what's the mix you expect between care reporting.
Thank you.
Yes, sure so I didn't catch the second one but I'll answer the other two and then I'll ask you to repeat that when Doug.
So incentive comp is now in all of our financial plans or free cash or sorry free cash flow is now in our incentive incentive comp plans. So that answers that question from a capital deployment perspective.
We continue to remain acquisition first from a priority standpoint.
And so I think if you look at the last couple of years, we did for acquisitions in 18 for acquisitions in 19, we always look at a healthy pipeline I think you can expect us to be active there. The dollar amount may fluctuate, but I think thats still our priority here from a capital deployment, we ended leverage a little bit down versus the end of last year in our liquidity is much stronger.
For the refinancing and then in terms of where it's always been pretty consistent I think we're primarily focused on diagnostics and a life sciences and I think that's it I mean, we you cut out on the second question there Doug what was the second question.
Ah, yes, sorry about that Jamie what are your assumptions for growth by geography.
What you embedded in <unk> revenue growth guidance for the year.
Yes.
Good question so.
Basically we're pretty much mid single digit across the board or if you look at Americas and Asia Pac that's been mid single digits. All 2019, Europe was low single digits.
We expect advantage. This to you know kind of revenue to clip that over into maybe the mid single digits ran at call. It a weaker mid single digits, so pretty consistent across the board and pretty consistent with what we saw in 2019.
Okay. Thank you.
Thank you.
Our next question comes from Jack <unk> with Barclays. Your line is open.
Thanks, Good afternoon.
I wanted to start maybe move back to D.A.S. I was curious what you're seeing from your industrial customers what that grew in the fourth quarter and just given the current state of the macro what the 2020 guidance assumes there in terms of progression.
So I think I'll talk about Fourq, you have to start with Jamie Yeh for Q was flat a consistent with where it's been most of the year Jack.
And then for 2020.
We're expect no change industrial environmental has been remarkably consistent for us a pretty flat throughout the entire year and I think that's up to our operating assumption going into 2020.
Great. Okay, and then back on the diagnostics business I wanted to follow up on the genetic testing lab, but just marking to market what was the final contribution for 2019.
What does the guidance assume for 2020 contribution.
And given the pace of the transition is there any additional timing dynamic there assumed for the first quarters wall.
Yeah. So 2019 genomic testing did extremely well obviously was much stronger in the first half.
Then the second half it was probably a little under $20 million in total <unk> in terms of 2020, I think we'd rather not give specific guidance here, but you can expect that it's gonna grow substantially.
And you know in terms of the cadence through the year I mentioned in my earlier remarks that the first quarter, we'll continue to be challenged because the consultation is not supposed to happen until the well it's happening right now in the the real real back there and it is a hiring we feel good about it but sometimes it can take two to three months to onboard.
People in that space and so we feel like the second quarters, when we'll start to ramp back up again and.
So overall, we expect another healthy incremental growth driver from genomics testing in 2020.
Great I could squeeze in one more what were the individual contributions from May thing and this bio the acquired growth NDS was a little bit higher than or looking for just was there anything.
Outside of the contributed in the quarter.
No not really know a spouse and managing both continue to do well I think we said imaging had been growing into the 20% plus range and you know continues to perform well, we got a thing 11 or out of 13 weeks or something in the quarter from them.
Insist bio has been double digit all year.
Great. Thanks, Jamie.
Thanks Jack.
Thank you. Our next question comes from Brandon Couillard.
With Jefferies. Your line is open.
Thanks, Good afternoon.
It's a holiday.
Curious if you could just touch on the services business for a minute I know you did some restructuring there in the third quarter I'm just curious what your outlook is for the one source business specifically enterprise services.
Look into 20.
Yeah, Brian and I think you know in terms of the services business. We did some oh no restructuring as you've seen this was again in the with the implementation of Servicemax, we continue to sort of see productivity coming out of there.
I think as we look forward to be AR, VR and a good position for Oh, 2020, and we expect to have in some tenders and I think as we've said at the continued to be high single digit growth business for us.
I said, one just for Jamie on the tax rate ticking up a little bit this year or is there anything specific behind that or just a and added level of conservatism sort of embedded for the tax rate.
No yeah I mean, it's good question Brandon It had gotten down to about 14% in 2018, we guided 16% for the year.
And came in at 15% so there she's a little natural uptick in tax I think if you look at where we are growing you look at your own Mewn you look at informatics enterprise.
A lot of those areas are higher tax jurisdictions. So therefore, we do anticipate that to go up a little and then the offset to that which is difficult to ER to forecast or some of the discrete items. We always have tax planning items, we had a lot in 2000, and a 19, which basically brought us from the 16% on a 15% but.
There is a little natural upward pressure there that makes us think that 16% at the right number.
Good thank you.
Thank you.
Thank you next quiet our next question comes from Dan Leonard with Wells Fargo. Your line is open.
Thank you a couple of things one prolonged you teased us with some potential proof points coming in 2020 as a result of the combined efforts of the organization are these whether they'd be new product introductions are service efforts or what have you are these things. It would have an impact in 2020 or are these things that would build and have a further impact in 2021 and beyond.
I think we've started seeing some of the benefits already you know as I pointed out the home cannabis workflows solutions that you have seen odd that I'd be. Another example is off all babies combined are a sample prep our business from the applied genomics sides with reagents a from a life sciences business. So we've started seeing.
Proof points of this and I don't think it's going to be a discrete 2020, I'd definitely continued to be ongoing and we expect to see a you know more synergistic opportunities coming out of this.
Okay, and then secondly can you walk me through your strategy to go from you mentioned the PLD code or can you walk through your strategy to go from that play code to getting that code included in medical coverage policies for NPT.
I think you know just getting the the code offers us the advantage that doesn't manufacturer, we can devote negotiate reimbursement rates directly but beers and direct billing.
On a methodology that would be specific to granted this a night BP and that hopefully all frustrated reimbursement rate for the border trees and you know and also additionally, we can build insurance without any this girlfriend color coding.
So I think you know that's the 11 I want to share just given the our competitive situations and for commercial reasons, but at this point earlier, what I would say is that we're really excited for what EM is acceptance of our pls called a that came in at the end of December and right. Now you got all hands on to ensure that ER.
Submissions getting diamond and because the Oh, we get the code in hand.
Okay. Thank you and then just final cleanup for Jamie Gimi that what was the China growth rate in Q4 was it consistent with the mid single digits of APAC or was it higher or lower than that.
Consistent with a pack Dan Thank you.
No problem.
We have a question from Paul Knight with Janney Montgomery Your line is open.
Thanks for the time the.
I I know the product portfolio clearly benefited from a candidates and food safety testing is there any goal you wouldn't have are pointing out on the R&D that you want to spend this year is an increasing faster than revenue and what are the some of the areas you'd like to develop further.
Yeah, Hi, overall R&D, if you look at it in 2019, yeah, we actually saw a little bit of efficiency and that was related to some of the the organizational restructuring we want that to be ticking up a little bit overtime and so what's embedded in this guidance is kind of a constant R&D as a percent of sales if anything maybe.
A little bit of uptick.
You mentioned candidates in food, that's one of the areas that were increasing some of our budgets are and I think in general, we're putting a little bit more resources between behind life Sciences diagnostics in food.
And I think you can expect that R&D as a percent of revenue will be at least flat if not up a little bit this year.
Okay. Thank you.
Yep.
Thank you. Our next question comes from Dan Brennan.
Your line is open.
Great. Thank Rob Thanks for the question, who Jamie a prolonged just wondering for Das I don't know if you guys broke out exactly whats baked in for 2020 guidance overall and then maybe we didn't then I know you touch on of applying environment, but could you break down a little bit food and Biopharma, both were salander, yet or kind of whats baked in going forward and once you know kind of what does the outlook.
Yeah, I think I think we're optimistic that asked a upticks here and maybe it's a point or appointing a half or if you look at food I mentioned it earlier I mean, we expect some kind of rebound in core food <unk> fourth quarter was a good data point, a if nothing else theres. Some good comp here obviously.
It's difficult to predict weather and climate change and if that impacts us then.
That will be different than what we're planning on but core food should rebound.
I mentioned that cannabis will have a slight offset to that though that we're not expecting as much incremental contributors, but net net I think food picks up a little bit.
Life Sciences, I think ticked up a little bit we talked about on for a lot of talked about some of our enterprise business going well and some extra tenders.
And an extra week here I think spy and informatics continues to be extremely strong both for double digit. This year, we're planning them more in the high single digit range. So we haven't seen anything but I just don't think we're going to plan them at double digits. So net net that probably upticks, a little bit and then industrial environmental we're planning flat so no change.
Isn't 19.
So he makes a little bit of improvement in life Sciences in food, you, probably uptick a little bit in das year over year.
Great. Thank you and then and then if you kind of pull this go back a little bit I know like a year or so ago. The conversation with maybe kind of high single digit growth type of portfolio, which obviously you guys still sound very constructive on the momentum that you have with all the business changes, but when you think about the 2020 guidance given a lot of color on the different businesses, but how.
Would you characterize the 5% balance towards or conservatism in it and how to call out of swing factor on the upside or downside what would that be thank you.
Yeah, then I think you know look again, we continued to be very excited about the portfolio under prospects that we have for accelerating profitable growth you've got a lot of funds in the fire I think entering the year over year trying to be balanced you know given a you know there are some much uncertainties that we see.
No and again you know.
For example, the Jimmy talked about just coming in as it is with the gardener wireless you don't know how that plays out but you know essentially the growth accelerates is that the have are inherently the swing factors that could be a very important goal as we look forward.
Okay, great. Thank you.
Thank you we have a question from Bill Quirk with Piper Sandler Your line is open.
Great. Thanks, Good evening, everybody. So a couple of questions from me first off a prolonged really do appreciate all the advantages commentary is there any just I guess.
Last question, maybe in that any particular geography or customer type, where you're seeing outsized interest and success and tourism placements and then secondly, I'm just staying in diagnostics for a moment with respect to the Corona virus assay development.
The CDC had some emergency procedures in place to be able to rapidly disseminate task for regulatory standpoint.
Familiar are you aware of the similar type of program in any of the other affected countries. Thanks.
Yeah, and Bill just stopping grid or you know your first question around managed this I think you know from an interest perspective, you are seeing interest and all the three <unk> all the three regions.
Hey pack ex China, given that we don't have approval in China, yet I've, you're going through the clinical in Europe and of course with the recent ER launch that we did in a in the U.S., we continued to see a broad spread or interest on it.
In regards to your second question, a yes or no similar to the CPC.
These cfd, a the a and B and C of D.A. in China also has oh accelerated or emergency processes that they haven't plays and we are working with them to get a desktop hopefully a in a few weeks.
Great. Thank you very much.
Huh.
Thank you and we have a question from Derik de Bruin with Bank of America. Your line is open.
Hey, great. Thanks for taking the follow up just one question I just I just wanted to clarify some since I got a bunch of questions from investors. So.
Typically the rule of thumb when you look at extra days is about a half a percent organic revenue growth is contribution for consumable have you companies. So yes, the $10 million to $15 million seems a little bit white in terms of revenue contribution on the extra week did I hear you correctly and saying you saw some of that was pull forward into the fourth quarter.
I'm just trying to say to make sure that is because it just seems like it's a lower number than I would've thought given your business mix.
Overall, it's 1.5% to 2% so the rule of thumb of half a percent times five wrong there.
Really I guess, a half a percent to a percent off here.
So I don't think its two different than what we saw in Threeq you 15, nor the rule of thumb overall I did say that yeah. I mean, if you look at December Thirtyth and 31st.
I think most customers operate on a calendar budget and that our salesforce probably much like every other year.
Looks at the Capex spending and says lets execute those before December 29th and.
I don't think that's any different than what we've done in most years. So.
I think it's pretty much noise around the up around the fringes here.
Okay, great. Thanks, just want to clarify thank you.
Thank you there are no other question of the queue I'd like to turn the call back to prolong thank for any closing remarks.
Thank you all for your questions as we've shared today, we have a number of exciting opportunities on the horizon as we continue to drive towards our mission and Exelate outcomes for the betterment of people and the environment.
I look forward to updating you on our continued progress in 2020. Thank you.
Ladies and gentlemen. This concludes today's conference call. Thank you for participating you may now disconnect everyone have a great day.
Oh.